Mechelen, Belgium

Tom Roger Lisette De Munck

This inventor holds 3 USPTO granted patents and 3 published patent applications and 2 EPO patents. Top assignees: Galapagos Nv, Abbvie S.a.r.l.. Active years: 2016-2018.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Tom Roger Lisette De Munck. Retrieved from https://idiyas.com/inventor/tom-roger-lisette-de-munck

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 3 

% Patents Active = 100.0

 

Average Co-Inventor Count = 8.3

ph-index = 1

Forward Citations = 2(Granted Patents)


Company Filing History:


Years Active: 2016-2018

Loading Chart...
Loading Chart...
3 patents (USPTO):Explore Patents

Title: Tom Roger Lisette De Munck: Innovating Cystic Fibrosis Treatment

Introduction:

Tom Roger Lisette De Munck is an inventor based in Mechelen, BE, renowned for his impactful contributions to the field of healthcare through his innovative patents. With a focus on developing compounds for the treatment of cystic fibrosis, De Munck has made significant strides in improving medical therapies.

Latest Patents:

De Munck holds three patents, with his latest inventions revolving around the development of compounds for treating cystic fibrosis. The first patent involves substituted pyridines and their method of use in treating the condition. The second patent delves into compounds and pharmaceutical compositions specifically designed for combating cystic fibrosis effectively.

Career Highlights:

Throughout his career, De Munck has been associated with reputable companies such as Galapagos NV and AbbVie S.à.r.l., where he has honed his skills and expertise in pharmaceutical research and development. His dedication to advancing treatment options for cystic fibrosis has positioned him as a key player in the healthcare industry.

Collaborations:

De Munck has collaborated with esteemed professionals in the field, including Hans Kelgtermans and Steven Emiel Van der Plas. Through these collaborations, he has been able to leverage diverse perspectives and insights to further enhance his innovative projects aimed at improving the lives of cystic fibrosis patients.

Conclusion:

Tom Roger Lisette De Munck's relentless pursuit of groundbreaking solutions for cystic fibrosis treatment underscores his commitment to driving innovation in healthcare. His patents stand as testaments to his ingenuity and dedication to making a tangible impact in the medical field. Through his collaborations and career milestones, De Munck continues to inspire and shape the future of pharmaceutical research.

Profile summary based on public USPTO records.
Data Sources: USPTO Patent Grant XML, Patent Center, EPO & CIPO • Normalized by IDiyas Innovation Graph. Methodology & provenance architecturePlease report any incorrect information to [email protected]
Loading…